AXSM Stock: Price, Earnings History and SEC Filings
Axsome Therapeutics, Inc. (AXSM) last traded at $144.43, up 0.68% on the latest session and down 21.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.99 against an analyst estimate of $-0.99, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AXSM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.99 | $-0.99 | +0.00% |
| Mar 2026 | May 4, 2026 | $-1.26 | $-0.85 | -48.24% |
| Dec 2025 | Feb 23, 2026 | $-0.71 | $-0.70 | -1.43% |
| Sep 2025 | Nov 3, 2025 | $-0.94 | $-0.82 | -14.63% |
AXSM beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How AXSM reacts to earnings
Across its last 8 earnings releases, AXSM moved 3.9% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-10 | Before open | +3.83% |
| 2026-05-04 | Before open | +8.31% |
| 2026-02-23 | Before open | -4.88% |
| 2026-01-12 | Before open | +4.39% |
| 2025-11-03 | Before open | +0.56% |
| 2025-08-04 | Before open | +3.42% |
| 2025-05-05 | Before open | +3.81% |
| 2025-02-18 | Before open | -2.33% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AXSM financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $638M | -$183M | -$94M | -28.7% | $-3.68 |
| 2024 | $386M | -$287M | -$129M | -74.5% | $-5.99 |
| 2023 | $271M | -$239M | -$146M | -88.4% | $-5.27 |
| 2022 | $50M | -$187M | -$117M | -374.0% | $-4.60 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AXSM
- 10-Q · Aug 10, 2026
- 8-K · Aug 10, 2026Results of operations, Other events, Financial statements and exhibits
- 8-K · Jul 15, 2026Other events, Financial statements and exhibits
- 8-K · Jun 9, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 9, 2026Shareholder vote, Financial statements and exhibits
- 8-K · Jun 3, 2026Other events, Financial statements and exhibits
- 10-Q · May 4, 2026
- 8-K · May 4, 2026Results of operations, Other events, Financial statements and exhibits
- 8-K · Apr 30, 2026Other events, Financial statements and exhibits
- DEF 14A · Apr 24, 2026
Insider filing activity
AXSM insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AXSM news
- Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?Oct 29, 2026 · fool.com
- Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityOct 28, 2026 · fool.com
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 27, 2026 · finance.yahoo.com
- Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowOct 26, 2026 · finance.yahoo.com
- 2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)Oct 23, 2026 · fool.com
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?Oct 21, 2026 · finance.yahoo.com
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.